Table 2. Biochemical and metabolic parameters in SHR-CRP transgenic and wild-type controls treated with salsalate or placebo.
| Trait | SHR placebo | SHR salsalate | SHR-CRP placebo | SHR-CRP salsalate | P strain | P treatment | P interaction |
|---|---|---|---|---|---|---|---|
| Body weight (g) | 405±6 | 378±5* | 366±6 | 370±7 | 0.001 | NS | 0.02 |
| Relative weight of epididymal fat (g/100 g body weight) | 0.87±0.03 | 0.84±0.02 | 0.62±0.04 | 0.65±0.02 | <0.00001 | NS | NS |
| Relative weight of perirenal fat (g/100 g body weight) | 0.80±0.08 | 0.74±0.05 | 0.36±0.05 | 0.35±0.03 | <0.00001 | NS | NS |
| Relative liver weight (g/100 g body weight) | 3.12±0.06 | 3.15±0.06 | 3.93±0.13 | 3.81±0.120 | 0.00004 | NS | NS |
| Serum glucose (mmol/L) | 6.6±0.1 | 6.3±0.1 | 7.3±0.1 | 6.4±0.2* | 0.03 | 0.006 | 0.043 |
| Serum insulin (nmol/L) | 0.263±0.034 | 0.232±0.030 | 0.244±0.040 | 0.228±0.047 | NS | NS | NS |
| Serum triglycerides (mmol/L) | 0.59±0.04 | 0.48±0.04 | 0.65±0.08 | 0.56±0.10 | <0.00001 | NS | NS |
| Serum NEFA (mmol/L) | 0.41±0.04 | 0.30±0.01* | 0.31±0.03 | 0.36±0.03 | NS | NS | 0.005 |
| Serum cholesterol (mmol/L) | 1.57±0.08 | 1.05±0.03* | 1.47±0.09 | 1.48±0.09 | <0.05 | 0.005 | 0.004 |
| Serum HDL cholesterol (mmol/L) | 1.01±0.05 | 0.66±0.03* | 0.99±0.03 | 1.02±0.11 | 0.03 | 0.03 | 0.02 |
| Liver triglycerides (μmol/g) | 5.7±0.5 | 5.4±0.2 | 12.0±4.1 | 11.6±4.2 | 0.04 | NS | NS |
| Muscle gastrocnemius triglycerides (μmol/g) | 5.1±0.8 | 3.2±0.6 | 4.5±1.0 | 1.8±0.3 | NS | 0.002 | NS |
| Lipolysis WAT (NEFA μmol/g) | 2.35±0.29 | 2.37±0.31 | 2.41±0.15 | 4.19±0.26* | 0.003 | 0.002 | 0.005 |
| Lipolysis WAT (glycerol μmol/g) | 1.14±0.10 | 1.46±0.09 | 1.35±0.12 | 1.81±0.11 | 0.02 | 0.001 | NS |
| Fatty acid reesterification | 2.05±0.14 | 1.76±0.27 | 1.70±0.17 | 2.36±0.17* | NS | NS | 0.03 |
| Lipolysis in BAT (NEFA μmol/g) | 6.77±1.08 | 8.25±0.99 | 5.39±0.43 | 8.36±0.11 | NS | 0.04 | NS |
Two-way ANOVA results: “P interaction” denotes the significance of salsalate treatment x human CRP interaction (treatment x strain comparison)–salsalate treatment can protect against adverse effects that are dependent on human CRP. “P strain” denotes the significance of SHR-CRP vs. SHR controls (strain effects); “P treatment” denotes the significance of salsalate treatment vs. placebo (treatment effects). For comparisons versus controls, the Holm-Sidak test was used
* denotes P<0.05 significance of comparisons for salsalate vs. placebo treatment of nontransgenic SHR or transgenic SHR-CRP.
NS denotes not significant.